GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurogene Inc (NAS:NGNE) » Definitions » Gross-Profit-to-Asset %

Neurogene (Neurogene) Gross-Profit-to-Asset % : 0.00% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neurogene Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Neurogene's annualized Gross Profit for the quarter that ended in Mar. 2024 was $0.00 Mil. Neurogene's average Total Assets over the quarter that ended in Mar. 2024 was $208.96 Mil. Therefore, Neurogene's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 0.00%.

Neurogene Gross-Profit-to-Asset % Historical Data

The historical data trend for Neurogene's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurogene Gross-Profit-to-Asset % Chart

Neurogene Annual Data
Trend Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
- - -

Neurogene Quarterly Data
Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross-Profit-to-Asset % Get a 7-Day Free Trial - - - - -

Competitive Comparison of Neurogene's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Neurogene's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurogene's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurogene's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Neurogene's Gross-Profit-to-Asset % falls into.


Neurogene Gross-Profit-to-Asset % Calculation

Neurogene's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (109.265+222.573)/ 2 )
=0/165.919
=0.00 %

Neurogene's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (222.573+195.35)/ 2 )
=0/208.9615
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Neurogene Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Neurogene's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurogene (Neurogene) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurogene Inc (NAS:NGNE) » Definitions » Gross-Profit-to-Asset %
Comparable Companies
Traded in Other Exchanges
N/A
Address
535 W 24th Street, 5th Floor, New York, NY, USA, 10011
Website
https://www.neurogene.com
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.

Neurogene (Neurogene) Headlines

From GuruFocus

Neurogene Announces Business Update and 2024 Outlook

By Business Wire • 01-05-2024

Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million

By Business Wire • 12-19-2023